CHRS vs. MGX, GLUE, AGEN, ZURA, CMPX, ABOS, IPHA, STRO, OPT, and INMB
Should you be buying Coherus BioSciences stock or one of its competitors? The main competitors of Coherus BioSciences include Metagenomi (MGX), Monte Rosa Therapeutics (GLUE), Agenus (AGEN), Zura Bio (ZURA), Compass Therapeutics (CMPX), Acumen Pharmaceuticals (ABOS), Innate Pharma (IPHA), Sutro Biopharma (STRO), Opthea (OPT), and INmune Bio (INMB). These companies are all part of the "biological products, except diagnostic" industry.
Coherus BioSciences (NASDAQ:CHRS) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, earnings, profitability, institutional ownership, media sentiment, valuation and risk.
In the previous week, Metagenomi had 13 more articles in the media than Coherus BioSciences. MarketBeat recorded 17 mentions for Metagenomi and 4 mentions for Coherus BioSciences. Coherus BioSciences' average media sentiment score of 0.00 beat Metagenomi's score of -0.30 indicating that Coherus BioSciences is being referred to more favorably in the media.
Coherus BioSciences presently has a consensus target price of $8.83, indicating a potential upside of 314.71%. Metagenomi has a consensus target price of $17.83, indicating a potential upside of 158.83%. Given Coherus BioSciences' higher possible upside, equities analysts clearly believe Coherus BioSciences is more favorable than Metagenomi.
72.8% of Coherus BioSciences shares are held by institutional investors. 7.6% of Coherus BioSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Coherus BioSciences received 427 more outperform votes than Metagenomi when rated by MarketBeat users. However, 90.00% of users gave Metagenomi an outperform vote while only 65.07% of users gave Coherus BioSciences an outperform vote.
Metagenomi has a net margin of 0.00% compared to Coherus BioSciences' net margin of -19.64%.
Metagenomi has lower revenue, but higher earnings than Coherus BioSciences.
Summary
Metagenomi beats Coherus BioSciences on 8 of the 14 factors compared between the two stocks.
Get Coherus BioSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Coherus BioSciences Competitors List
Related Companies and Tools
